Medication info
Neurocava-Peji Capsule 150mg (Pregabalin)

Neurocava-Peji Capsule 150mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a white upper part and a white lower part containing a white to pale yellow powder.
Packaging
For domestic use - 30 capsules/bottle, For domestic use - 100 capsules/bottle, For export - 30 capsules/box[((10 tablets/PTP)*3)]
Approval status
Active

MFDS item code 201108886 · Approved 2011.10.20 · Insurance code 647803570

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section ‘5. Patients with renal impairment’). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section ‘4. Discontinuation’). 2. Epilepsy Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily pregabalin dose should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosage regimen. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults and as an adjunct for partial seizures in patients with epilepsy, with or without secondary generalized symptoms. It is also effective in the treatment of fibromyalgia. It helps improve various symptoms related to neurological disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section ‘5. Patients with renal impairment’). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section ‘4. Discontinuation’). 2. Epilepsy Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily pregabalin dose should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosage regimen. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or actions, so if any symptoms of depression or mood changes occur while taking this medication, consult a doctor immediately. Those with an allergy to pregabalin or any components of this medication should not take it. Diabetic patients may be affected by blood sugar control due to weight gain, so dosage adjustments for hypoglycemic medications may be necessary. If symptoms of angioedema appear, discontinue use immediately and inform your doctor. Elderly patients should be cautious of fall risks due to dizziness or drowsiness, particularly when starting the medication. Temporary blurred vision or changes in eyesight can occur, and if such symptoms arise, consult your doctor. Abrupt discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety, so dosage should be gradually reduced according to your doctor's instructions. Patients with a history of substance abuse are at higher risk of misuse of this drug and should take it with extra caution. Dose adjustments may be required for patients with decreased kidney function. Patients with heart disease should be cautious when using this medication. Caution is advised when taking it with opioid analgesics as it may increase the risk of central nervous system depression. Patients with respiratory diseases or kidney impairment, as well as elderly individuals, may have a higher risk of severe respiratory depression, and dose adjustments may be necessary. Pregnant women should avoid taking this medication in early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. If breastfeeding, consult with your doctor as this medication can be transferred through breast milk and affect the baby. Caution is advised when driving or operating machinery due to the risk of accidents from dizziness or drowsiness until the symptoms have completely resolved. Rarely, severe skin adverse reactions can occur, so discontinue use and inform medical personnel if a rash or redness develops. Overdose may cause confusion, drowsiness, and seizures, which require immediate emergency treatment. Keep this medication out of reach of children, and do not transfer it to other containers.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper airway swelling
  • dizziness
  • drowsiness
Show 202 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like symptoms
  • restlessness
  • depression
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • drug misuse
  • abuse
  • dependence
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paroxysmal dysesthesia
  • restlessness
  • mood swings
  • emotional lability
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • abnormal coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • muscle hypotonia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • diplopia
  • dry eyes
  • conjunctival edema
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • depth perception changes
  • strabismus
  • bright vision
  • dizziness
  • auditory hypersensitivity
  • 1st-degree AV block
  • tachycardia
  • bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle spasms
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle cramps
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • swelling
  • gait abnormalities
  • falling
  • feeling drunk
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • loss of consciousness
  • mental disorders
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion state
  • depression
  • agitation
  • restlessness
  • convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 15°C and 30°C.

Appearance and packaging

Appearance

A hard capsule with a white upper part and a white lower part containing a white to pale yellow powder.

Package unit

For domestic use - 30 capsules/bottle, For domestic use - 100 capsules/bottle, For export - 30 capsules/box[((10 tablets/PTP)*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.